Supplementary Material*

Hernandez AV, Roman YM, Pasupuleti V, et al. Update alert 3: hydroxychloroquine or chloroquine for the treatment or prophylaxis of COVID-19. Ann Intern Med. 21 October 2020. [Epub ahead of print]. doi:10.7326/L20-1257

Item	Page
Supplement Table. Effect of Hydroxychloroquine Reported in Controlled Studies	2

* This supplementary material was provided by the authors to give readers further details on their article. The material was reviewed but not copyedited.

Supplement Table. Effect of Hydroxychloroquine Reported in Controlled Studies

Name	Type	RoB	Unadjusted Absolute effect of HCQ vs. Control (95% CI)	SOE
All-Cause Mortality				
Abd-Elsalam[4]	RCT	H	HCQ: 6/97 vs. 5/97; RD 1.0% (-5.5% to 7.5%)	L
Cavalcanti[10]		H	HCQ: 5/159 vs. 5/173; RD 0.3% (-3.4% to 3.9%)	
Cavalcanti[10]		H	HCQ+AZ: 3/172 vs. 5/173; RD -1.2% (-4.3% to 2.0%)	
Mitjà[11]		SC	HCQ: 0/136 vs. 0/157; RD 0% (NA)	
Skipper[12]		H	HCQ: 1/201 vs. 1/194; RD -0.02% (-1.4% to 1.4%)	
Horby[13]		SC	HCQ: 418/1561 vs. 788/3155; RD 1.8% (-0.9% to 4.5%)	
C-P Chen[14]		SC	HCQ: 0/21 vs. 0/12; RD 0% (NA)	
J Chen[15]		SC	HCQ: 0/15 vs. 0/15; RD 0% (NA)	
L Chen[16]		H	HCQ: 0/15 vs. 0/12; RD 0% (NA)	
Sulaiman[5]	Cohort	S	HCQ: 7/1817 vs. 54/3724; RD -1.1% (-1.5% to -0.6%) ǂ	L
Catteau[6]		S	HCQ: 804/4542 vs. 957/3533; RD -9.4% (-11.2% to -7.5%) ǂ	
Di Castelnuovo[7]		S	HCQ: 386/2634 vs. 190/817; RD -8.6% (-11.8% to -5.4%) ǂ	
Ip[8]		S	HCQ: 2/97 vs. 44/970; RD -2.5% (-5.6% to 0.6%)	
Kalligeros[9]		S	HCQ±AZ: NA/36 vs. NA/72; aHR 0.82 (0.20 to 3.24)*	
Paccoud[17]		S	HCQ: 3/38 vs. 6/46; RD -5.2% (-18.1% to 7.8%)	
Lecronier[18]		C	HCQ: 9/38 vs. 9/22; RD -17.2% (-41.8% to 7.4%)	
Barbosa[19]		C	HCQ: 4/31 vs. 1/32; RD 9.8% (–3.5% to 23.3%)	
Magagnoli[20]		S	HCQ±AZ: 27/97 vs. 18/158; RD 16.4% (6.2% to 26.6%)ǂ	
Mallat[21]		S	HCQ: 0/23 vs. 0/11 [0%]; RD 0% (NA)	
Membrillo[22]		C	HCQ: 27/123 vs. 21/43; RD -26.9% (-43.5% to -10.3%) ǂ	
Geleris[23]		M	HCQ±AZ: 157/811 vs. 75/565; RD 6.1% (2.2% to 10%) ǂ	
Rosenberg[24]		S	HCQ±AZ: 54/271 vs. 28/221; RD 7.3% (0.8% to 13.7%) ǂ	
Mahévas[25]		S	HCQ: 9/84 vs. 8/97; RD 2.5% (-6.1% to 11.1%)	
Ip[26]		S	HCQ: 383/1914 vs. 120/598; RD -0.1% (-3.7% to 3.6%)	
Sbidian[27]		M	HCQ: 111/623 vs. 830/3792; RD -4.1% (-7.4% to 0.8%)	
Singh[28]		S	HCQ: 104/910 vs. 109/910; RD -0.6% (-3.5% to 2.4%)	
Yu[29]		S	HCQ: 9/48 vs. 238/502; RD -29.7% (-40.5% to -16.8%) ǂ	
Arshad[30]		S	HCQ±AZ: 162/1202 vs. 108/409; RD -12.9% (-17.6% to -8.2%) ǂ	
Composite of Intubation or Death				
Horby[13]	RCT	SC	HCQ: 388/1300 vs. 696/2623; RD 3.3% (0.3% to 6.3%) ǂ	L
Geleris[23]	Cohort	M	HCQ±AZ: 262/811 vs. 84/565; RD 17.4% (13.1% to 21.8%) ǂ	I
Composite of ICU Admission Within 7-Days or Death				
Paccoud[17]	Cohort	S	HCQ: [By 12 days] 13/38 vs. 16/46; RD -0.6% (-21.0% to 19.9%)	I
Mahévas[31]		S	HCQ: 16/84 vs. 21/97; RD -2.6% (-14.3% to 9.1%)	
ICU Admission				
Sulaiman[5]	Cohort	S	HCQ: 14/1817 vs. 56/3724; RD -0.7% (-1.3% to -0.2%) ǂ	I

Catteau[6]		S	HCQ: 313/4539 vs. 96/3529; RD 4.2% (3.3% to 5.1%) ǂ	
Ip[8]		S	HCQ: 3/97 vs. 42/970; RD -1.3% (-4.9% to 2.4%)	
Rosenberg[24]		S	HCQ±AZ: 52/271 vs. 27/221; RD 7% (0.6% to 13.3%) ǂ	
Survival without ICU Admission				
Mahévas[25]	Cohort	S	HCQ: 17/84 vs. 22/89; RD -4.5% (-16.9% to 7.9%)	I
Need of Mechanical Ventilation				
Abd-Elsalam[4]	RCT	H	HCQ: 4/97 vs. 5/97; RD -1.0% (-6.9% to 4.9%)	
Cavalcanti[10]		H	HCQ: 12/159 vs. 12/173; RD 0.6% (-5.0% to 6.2%)	L
Cavalcanti[10]		H	HCQ+AZ: 19/172 vs. 12/173; RD 4.1% (-1.9% to 10.1%)	
Mitjà[11]		SC	HCQ: 0/136 vs. 0/157; RD 0% (NA)	
Horby[13]		SC	HCQ: 118/1300 vs. 215/2623; RD 0.9% (-1.0% to 2.8%)	
Lecronier[18]	Cohort	C	HCQ: 5/38 vs. 2/22; RD 4.1% (-12.1% to 20.2%)	L
Magagnoli[20]		S	HCQ±AZ: 12/90 vs. 25/177; RD -0.8% (-9.5% to 7.9%)	
Mallat[21]		S	HCQ: 0/23 vs. 0/11; RD 0% (NA)	
Geleris[23]		M	HCQ±AZ: 154/811 vs. 26/565; RD 14.4% (11.2% to 17.6%) ǂ	
Rosenberg[24]		S	HCQ±AZ: 51/271 vs. 18/221; RD 10.7% (4.8% to 16.6%) ǂ	
Singh[28]		S	HCQ: 46/910 vs. 57/910; RD -1.2% (-3.3% to 0.9%)	
Severe Disease Progression				
J Chen[15]	RCT	SC	HCQ: 1/15 vs. 0/15; RD 6.7% (-6.0% to 19.3%)	I
L Chen[16]		H	HCQ: 0/15 vs. 0/12; RD 0% (NA)	
Z Chen[32]		SC	HCQ: 0/31 vs. 4/31; RD -12.9% (-24.7% to -1.1%) ǂ	
Barbosa[19]	Cohort	C	HCQ: [Respiratory support level] +0.63±0.79 vs. +0.16±0.64 points; MD 0.47 (0.11 to 0.83) ǂ	I
Mallat[21]		S	HCQ: [High flow oxygen therapy] 0/23 vs. 0/11; RD 0% (NA)	
Mahévas[31]		S	HCQ: [ARDS] 24/84 vs. 23/95; RD 4.4% (-8.6% to 17.3%)	
Hospitalization				
Mitjà[11]	RCT	SC	HCQ: 8/136 vs. 11/157; RD -1.1% (-6.7% to 4.5%)	L
Skipper[12]		H	HCQ: 4/212 vs. 10/211; RD: -2.9% (-6.3% to 0.6%)	
Sulaiman[5]	Cohort	S	HCQ: 171/1817 vs. 617/3724; RD -7.2% (-9.0% to -5.4%) ǂ	I
Ip[8]		S	HCQ: 21/97 vs. 305/970; RD -9.8% (-18.5% to -1.1%) ǂ	
Komissarov[33]		C	HCQ: 7/33 vs. 0/10; RD 21.2% (7.3% to 35.2%) ǂ	
Discharge from Hospital				
Horby[13]	RCT	SC	HCQ: 941/1561 vs. 1982/3155; RD -2.5% (-5.5% to 0.4%)	L
Paccoud[17]	Cohort	S	HCQ: 21/38 vs. 26/46; RD -1.3% (-22.6% to 20.1%)	I
Mahévas[25]		S	HCQ: 67/84 vs. 71/89; RD 0% (-12% to 12%)	
Sbidian[27]		M	HCQ: 351/623 vs. 1507/3792; RD 16.6% (12.4% to 20.8%)	
Symptom Resolution				
Skipper[12]	RCT	H	HCQ: [At 14 days:] 152/201 vs. 135/194; RD 6.0% (-2.7% to 14.8%)	I
J Chen[15]		SC	HCQ: [Fever] 1 vs. 1 day; MD 0 days (NA)	
L Chen[16]		H	HCQ: [Days to recovery [Median(IQR)]]: 6 (3-8) vs. 7.5 (5-16.3)	
Z Chen[32]		SC	HCQ: [Fever] 2.2±0.4 vs. 3.2±1.3 days; MD -1 day (-1.5 to -0.5) ǂ [Cough] 2.0±0.2 vs. 3.1±1.5 days; MD -1.1 days (-1.6 to -0.6) ǂ	
Tang[34]		H	HCQ: [Composite symptom resolution] 32/64 vs. 24/55; RD 6.4% (-11.6% to 24.3%)	
Abd-Elsalam[4]		H	HCQ: [Complete recovery] 52/97 vs. 33/97; RD 19.5% (5.9% to 33.3%)	
Kalligeros[9]	Cohort	S	HCQ±AZ: [Days to improvement] MD +0.23 days (-1.87 to 2.33)**	I

			HCQ±AZ: [Days to fever resolution] MD +1.27 days (-0.49 to 3.03)**	
Progression of Pulmonary Lesions on CT Scan				
J Chen[15]	RCT	SC	HCQ: 5/15 vs. 7/15; RD -13.3% (-48.1% to 21.4%)	L
Z Chen[32]		SC	HCQ: 2/31 vs. 9/31; RD -22.6% (-40.8% to -4.4%) ✝	
Improvement in Pulmonary Lesions on CT Scan				
Z Chen[32]	RCT	SC	HCQ: 25/31 vs. 17/31; RD 25.8% (3.4% to 48.2%) ✝	I
Upper Respiratory Virological Clearance				
C-P Chen[14]	RCT	SC	HCQ: [Day 14] 17/21 vs. 9/12; RD 6.0% (-23.8% to 35.7%)	I
J Chen[15]		SC	HCQ: [Day 7] 13/15 vs. 14/15; RD -6.7% (-28% to 14.7%) [Day 14] 15/15 vs. 15/15; RD 0% (NA)	
L Chen[16]		H	HCQ: [Day 10] 15/15 vs/ 12/12; RD 0% (NA)	
Tang[34]		H	HCQ: [Day 23] 53/75 vs. 56.75; RD -4% (-18.3% to 10.3%)	
C-P Chen[14]	Cohort	C	HCQ: [Day 14] 12/28 vs. 5/9; RD -12.7% (-50.0% to 24.6%)	I
Lecronier[18]		C	HCQ: [Day 7] 7/26 vs. 2/14; RD 12.6% (-12.4% to 37.7%)	
Mallat[21]		S	HCQ: [Day 14] 11/23 vs. 10/11; RD -43.1% (-69.6% to -16.5%) ✝	
Gautret[35]		C	HCQ±AZ: [Day 6] 14/20 vs. 2/16; RD 57.6% (31.8% to 83.3%) ✝	

RoB: Risk of bias; HCQ: Hydroxychloroquine; SOE: Strength of evidence; 95%CI: 95% confidence interval; RCT: Randomized controlled trial; RD: Absolute risk difference; MD: Mean difference; ARDS: Acute respiratory distress syndrome. ✝ denotes a statistically significant finding. Risk of Bias Codes: SC – some concerns, H– high, M – moderate, S –serious, C – critical, NI – no information; Strength of Evidence Codes: I – insufficient, L- low.
*adjusted hazard ratio, number of events per treatment group not provided.
**mean difference, mean values and standard deviation per treatment group not provided.